PKM and chronic myelogenous leukemia, BCR-ABL1 positive: Remarkably, KEGG GO enrichment analysis revealed that PKM2 substrates are enriched in prostate, endometrial thyroid, colorectal, chronic myeloid leukemia and non-small cell lung cancer pathways, as well as in cancer associated pathways, such as DNA repair and cell cycle pathways (Fig. 2F), in line with the facts that PKM2 is preferentially expressed in most cancers.